[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2021004396A - Metodos y composiciones para el tratamiento de la mucositis oral. - Google Patents

Metodos y composiciones para el tratamiento de la mucositis oral.

Info

Publication number
MX2021004396A
MX2021004396A MX2021004396A MX2021004396A MX2021004396A MX 2021004396 A MX2021004396 A MX 2021004396A MX 2021004396 A MX2021004396 A MX 2021004396A MX 2021004396 A MX2021004396 A MX 2021004396A MX 2021004396 A MX2021004396 A MX 2021004396A
Authority
MX
Mexico
Prior art keywords
methods
compositions
oral mucositis
treating oral
treating
Prior art date
Application number
MX2021004396A
Other languages
English (en)
Inventor
Steven A Kates
Steven Parkinson
Patrick C O''connor
Original Assignee
Lakewood Amedex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lakewood Amedex Inc filed Critical Lakewood Amedex Inc
Publication of MX2021004396A publication Critical patent/MX2021004396A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen métodos y composiciones farmacéuticas que incluyen Bisfosfocinas para tratar la mucositis oral en un paciente.
MX2021004396A 2018-10-17 2019-10-17 Metodos y composiciones para el tratamiento de la mucositis oral. MX2021004396A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862746943P 2018-10-17 2018-10-17
PCT/US2019/056772 WO2020081839A1 (en) 2018-10-17 2019-10-17 Methods and compositions for treating oral mucositis

Publications (1)

Publication Number Publication Date
MX2021004396A true MX2021004396A (es) 2021-06-04

Family

ID=70281364

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021004396A MX2021004396A (es) 2018-10-17 2019-10-17 Metodos y composiciones para el tratamiento de la mucositis oral.

Country Status (12)

Country Link
US (2) US11123357B2 (es)
EP (1) EP3866810A4 (es)
JP (1) JP2022503733A (es)
KR (1) KR20210075968A (es)
CN (1) CN112839662A (es)
AU (1) AU2019361999A1 (es)
BR (1) BR112021006954A2 (es)
CA (1) CA3116157A1 (es)
IL (1) IL282100A (es)
MX (1) MX2021004396A (es)
SG (1) SG11202103180QA (es)
WO (1) WO2020081839A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12030908B2 (en) 2017-03-10 2024-07-09 Lakewood Amedex, Inc. Antimicrobial compounds, compositions, and uses thereof
US11795192B2 (en) * 2017-03-10 2023-10-24 Lakewood Amedex, Inc. Antimicrobial compounds, compositions, and uses thereof
WO2024129985A2 (en) * 2022-12-14 2024-06-20 Lakewood Amedex, Inc. Antiviral compounds, compositions, and uses thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4421769A (en) 1981-09-29 1983-12-20 The Procter & Gamble Company Skin conditioning composition
US5167950A (en) 1991-03-28 1992-12-01 S. C. Johnson & Son High alcohol content aerosol antimicrobial mousse
MX9604033A (es) 1994-03-11 1997-09-30 Procter & Gamble Composiciones cosmeticas de ph bajo, hidroliticamente estables que contienen activos acidos.
US6211349B1 (en) 1998-12-30 2001-04-03 Oligos Etc., Inc. Protonated/acidified nucleic acids and methods of use
US20020032164A1 (en) 1998-12-30 2002-03-14 Dale Roderic M. K. Antimicrobial compounds and methods for their use
US7868162B2 (en) 1998-12-30 2011-01-11 Lakewood-Amedex, Inc. Antimicrobial and antiviral compounds and methods for their use
US6211162B1 (en) 1998-12-30 2001-04-03 Oligos Etc. Inc. Pulmonary delivery of protonated/acidified nucleic acids
ID30093A (id) 1999-02-12 2001-11-01 Sankyo Co Analog-analog nukleosida dan oligonukleotida baru
US6946118B1 (en) * 1999-09-14 2005-09-20 Orapharma, Inc. Formulations for treating or preventing mucositis
US6156294A (en) 1999-11-28 2000-12-05 Scientific Development And Research, Inc. Composition and method for treatment of otitis media
EP1435970A4 (en) 2001-10-18 2005-05-04 Ilex Products Inc METHOD OF TREATING SKIN WITH DIPHOSPHONATE DERIVATIVES
ATE417616T1 (de) * 2002-05-21 2009-01-15 Abbott Lab Behandlung von mukositis
CN1687100A (zh) * 2005-04-05 2005-10-26 奥林格斯技术有限公司 修饰性核苷酸及其用途
US8227431B2 (en) 2008-03-17 2012-07-24 Hetero Drugs Limited Nucleoside derivatives
US8884000B2 (en) 2010-02-17 2014-11-11 Albert Einstein College Of Medicine Of Yeshiva University Saporin-L1 inhibitors and uses thereof
EP2601205A2 (en) 2010-08-03 2013-06-12 Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. Guanine nucleotide derivatives for treating bacterial infections
WO2013175377A2 (en) * 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of mucositis
WO2014124430A1 (en) 2013-02-11 2014-08-14 Emory University Nucleotide and nucleoside therapeutic compositions and uses related thereto
WO2015075406A1 (en) 2013-11-19 2015-05-28 Lipopeptide Ab New treatment of chronic ulcers
US20160120936A1 (en) 2014-10-30 2016-05-05 Karen Troxel Methods of preventing surgical site infections
US10172786B2 (en) * 2014-12-16 2019-01-08 Axim Biotechnologies, Inc. Oral care composition comprising cannabinoids
WO2017165673A1 (en) * 2016-03-23 2017-09-28 University Of Utah Research Foundation Spinal traction device
KR102317158B1 (ko) * 2017-03-10 2021-10-25 레이크우드 아메덱스, 인크. 항미생물 화합물, 조성물, 및 그의 용도
ES2981923T3 (es) * 2017-06-12 2024-10-11 Lakewood Amedex Inc Formulaciones en gel de bisfosfocinas y usos de las mismas

Also Published As

Publication number Publication date
WO2020081839A1 (en) 2020-04-23
JP2022503733A (ja) 2022-01-12
US11123357B2 (en) 2021-09-21
KR20210075968A (ko) 2021-06-23
US20210393666A1 (en) 2021-12-23
US20200121708A1 (en) 2020-04-23
SG11202103180QA (en) 2021-05-28
CN112839662A (zh) 2021-05-25
EP3866810A1 (en) 2021-08-25
BR112021006954A2 (pt) 2021-07-20
EP3866810A4 (en) 2022-07-27
CA3116157A1 (en) 2020-04-23
IL282100A (en) 2021-05-31
AU2019361999A1 (en) 2021-02-25

Similar Documents

Publication Publication Date Title
PH12020500066A1 (en) Carboxamides as modulators of sodium channels
PH12019501970A1 (en) Pharmaceutical compositions for combination therapy
GB2541571A (en) Pharmaceutical compositions
MX2022004983A (es) Composiciones de profarmaco y metodos de tratamiento.
PH12019501301A1 (en) Pharmaceutical compositions for combination therapy
MX2020011817A (es) Metodos para tratar el linfoma.
EP4289820A3 (en) Compounds for use in treating alzheimer's disease in apoe4+/+ patients
MX2017002489A (es) Agentes terapeuticos humanos.
MX2021004396A (es) Metodos y composiciones para el tratamiento de la mucositis oral.
MX2019014808A (es) Aparato de muestreo bucal y usos de este.
PH12018500254A1 (en) Combinations of an ox40 antibody and a tlr4 modulator and uses thereof
CR20220374A (es) Métodos de tratamiento de la esplenomegalia
CY1125113T1 (el) Συνθεσεις και μεθοδοι για χρηση στην αγωγη της ομοκυστινουριας
CY1119532T1 (el) (s)-πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
TW201713323A (en) Therapeutic compositions and methods of use thereof
MX2020013389A (es) Composiciones de terlipresina y usos de las mismas.
MX2022014792A (es) Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican.
CY1119522T1 (el) (r)- πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
PT3817689T (pt) Dispositivo de cicatrização para implante dentário
MX2021014806A (es) Composiciones para el cuidado bucal y sus usos.
IL250852B (en) Periodontal preparation
EP3843700A4 (en) COMPOSITIONS AND METHODS FOR DENTAL CARE
IL267081A (en) Compounds, methods and devices for improving dental treatments
EP3781262A4 (en) COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASE IN SELECTED PATIENTS
MX2022000082A (es) Composiciones terapeuticas y metodos para tratar canceres.